SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing intense community debate as the stock trades near 52-week lows, with investors weighing strong product growth and the Alani Nu integration against broader market concerns and margin pressures. The community is actively tracking upcoming earnings and potential institutional accumulation, while some investors interpret the recent price weakness as a short-term shakeout before a rebound.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is seeing significant trading volume and upward price movement driven by reports identifying the company as a key stealth supplier for AI data center components and potential AR smart glass projects. Market participants are actively discussing the stock's role in the co-packaged optics supply chain, with many debating whether the current rally represents a sustainable breakout supported by fundamental semiconductor demand or a volatile pump-and-dump scenario.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors focus on its strong fundamental performance, including a series of profitable quarters, and the potential for a technical breakout following recent AAA-rated asset-backed securities deals. The community is actively debating the stock's significant valuation gap compared to sector peers and analyzing how its AI-driven credit model and expanding institutional partnerships could trigger a rebound as the company prepares for upcoming earnings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility as investors weigh the company's strong revenue performance against ongoing regulatory skepticism from analysts. The community is actively debating the impact of a potential new late-stage study led by partner Roche, while bulls remain frustrated by what they perceive as aggressive market manipulation and disconnects between the firm's approved pipeline and its current valuation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is rallying following the acquisition of Mirantis, a move that integrates software orchestration and enterprise cloud services to pivot the company toward a full-stack AI infrastructure provider. The community is actively debating whether this strategic expansion, alongside substantial energy capacity, positions the stock for a long-term re-rating similar to other major data center players heading into its upcoming earnings.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is drawing significant investor attention as it rolls out an aggressive value-focused menu strategy, including items priced at three dollars or less, to combat recent traffic declines and address consumer concerns over affordability. While the community remains divided over the stock's long-term potential, ongoing discussions frequently highlight a clash between the company's defensive real estate model and persistent criticism regarding leadership direction and perceived food quality.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending as the community debates the validity of recent preclinical data for its ERNA-101 ovarian cancer candidate, with some investors highlighting the potential of the MD Anderson collaboration and high short interest, while others warn of a history of dilution and the speculative nature of early-stage mouse studies.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as investors weigh strong underlying enterprise growth and AI-driven demand against significant short-term volatility and sector-wide sentiment shifts. The community remains divided, with many traders debating whether recent pullbacks represent an attractive entry point for a long-term AI infrastructure play or a deeper valuation reset for the software sector.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending as it pre-announced better-than-expected revenue guidance and signaled the sunsetting of its ironSource Ads Network, fueling community speculation about a potential strategic turnaround. Investors are actively debating the stock's future, weighing these positive business updates against the significant short interest and lingering skepticism following previous management and growth struggles.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is driving intense community debate following a massive earnings beat that showcased significant revenue growth and profitability, though the stock has experienced whipsaw price action due to investor confusion over a routine shelf registration filing. The community remains heavily divided between long-term bulls who view the company as a high-margin AI profit machine and skeptics who are cautious of valuation risks and broader software sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and...

Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire Intel, SAP, Lunai Bioworks In Focus

U.S. stock futures were mixed on Friday following Thursday's decline, after President Donald Trump announced the extension of the ceasefire between Israel and Lebanon by three weeks. On Thursday, the...

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient...

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under...

AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up

Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD

Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures

Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.

<ul class="summary-bullets"><li>The deal would expand Lunai’s capacity to develop treatments for neurological disorders.</li><li>The transaction is executed through Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share.</li><li>The acquired technology enables compounds to remain inactive in the body until they reach the brain, where they are selectively activated.</li></ul>Lunai Bioworks, Inc. (LNAI) announced a $20 million acquisition to advance its central nervous system (CNS) drug development.&nbsp;The company will acquire blood-brain barrier (BBB) delivery technology and Alzheimer's therapeutic assets for $20 million from the Clemann Group, SAS, or its assignee, marking an expansion of Lunai’s capabilities in neurological drug research.<h2 class="st-heading-2">Transforming CNS Drug Delivery</h2>The transaction is structured as Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share, with a cap on beneficial ownership at 19.9% to remain compliant with Nasdaq regulations.&nbsp;The newly acquired delivery platform addresses one of the most persistent challenges in central nervous system (CNS) drug development, which is the effective transport of therapeutics across the blood-brain barrier.The technology ensures that compounds remain inactive in the body until reaching the brain, where they activate to target specific neurological pathways.&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks stock</a> traded over 25% higher on Thursday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Lunai’s Alzheimer’s Pipeline</h2>This acquisition directly strengthens Lunai’s Alzheimer’s program by combining validated target identification with a strong delivery method. The platform enables advanced treatments for CNS disorders where conventional drugs face penetration limitations, potentially improving both safety and effectiveness.&nbsp;<blockquote>&nbsp;"We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain.”— David Weinstein, CEO, Lunai Bioworks</blockquote>On March 19, Lunai launched the Pathfinder Consortium, a national academic-industry alliance to accelerate the development of chemical countermeasures for battlefield and terrorism threats.&nbsp;LNAI stock has declined by over 35% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-aiff-stock-surge-pre-market-today/cZ3rwPpRIjD">Why Did AIFF Stock Surge Over 20% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen

Why Did LNAI Stock Surge Over 25% Today? 

Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.

Equity

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI...

Best Manufacturing Stocks To Watch Today - March 17th

Taiwan Semiconductor Manufacturing, Applied Materials, and Lunai Bioworks are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Lunai Bioworks Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest LNAI News

LNAILunai Bioworks Inc.